- Trials with a EudraCT protocol (1)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1 result(s) found for: 2021-006386-38.
Displaying page 1 of 1.
EudraCT Number: 2021-006386-38 | Sponsor Protocol Number: 20210104 | Start Date*: 2022-06-02 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Amgen, Inc. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE 301) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: CZ (Ongoing) ES (Temporarily Halted) AT (Ongoing) IT (Ongoing) HU (Ongoing) BE (Ongoing) NL (Ongoing) PT (Ongoing) DK (Ongoing) FI (Completed) BG (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.